REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

Autor: Bennett Thilagar, Bradley Brown, Arnold L. Oronsky, Tony R. Reid, Nacer Abrouk, Corey A. Carter, Erica Burbano, Angelique Coyle, Bryan Oronsky, Scott Caroen, Gina Varner, Curtis Scribner, Lindsey Ferry, Christopher A. Larson, Mary Flanagan Quinn

Publikováno v: Future Oncology. 15:3427-3433

RRx-001 is a cysteine-directed anticancer alkylating agent with activity in a Phase II study in platinum refractory small cell lung cancer. Here, we describe the design of REPLATINUM, an open-label, Phase III trial. 120 patients with previously plati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb0750e6416fb0e065a006b84316412c
https://doi.org/10.2217/fon-2019-0317

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001

Autor: Christina Brzezniak, Mary Flanagan Quinn, Bruno Schmitz, Jan Scicinski, Bryan Oronsky, Aiste Degesys, Pedro Cabrales, John Jenkins, Tony R. Reid, Scott Caroen, Corey A. Carter, P. Gabriel Peterson

Publikováno v: Case Reports in Oncology
Case reports in oncology, vol 9, iss 1
Case Reports in Oncology, Vol 9, Iss 1, Pp 164-170 (2016)

Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4601de79543db51deb5057abe003d5
https://doi.org/10.1159/000444633

Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME)

Autor: Bryan T. Oronsky, Jeannie Williams, Christina Brzezniak, Mary Flanagan Quinn, Corey Carter, Scott Caroen

Publikováno v: Journal of Clinical Oncology. 38:e15119-e15119

e15119 Background: RRx-001 is a minimally toxic small molecule that downregulates CD47 via Myc inhibition and repolarizes tumor-associated macrophages (TAMs). A phase 1 pilot study was undertaken to determine the safety and feasibility of RRx-001 and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c34f002f09d80c6971fd38a695728ab9
https://doi.org/10.1200/jco.2020.38.15_suppl.e15119

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001

Autor: H. Lybeck, Jane B. Trepel, Christina Brzezniak, Corey A. Carter, Karen Zeman, Mary Flanagan Quinn, Scott Caroen, Regina M. Day, Arnold L. Oronsky, Nacer Abrouk, Jan Scicinski, Tony R. Reid, Bryan Oronsky, Pedro Cabrales, Christopher A. Larson

Publikováno v: Clinical Medicine Insights: Oncology, Vol 10 (2016)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 105-108 (2016)

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6122f64ee2dc398450df87eea0d80ecc
http://hdl.handle.net/10138/232079

Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775

Autor: Shivaani Kummar, Sheila A. Prindiville, Ganesh Mugundu, Lyndsay Harris, Mary Flanagan Quinn, Jiuping Jay Ji, Naoko Takebe, Khanh Tu Do, Robert J. Kinders, Richard Piekarz, Deborah Wilsker, Elad Sharon, Alice P. Chen, Ashley Bruns, Larry Rubinstein, Howard Streicher, Lamin Juwara, Geraldine O'Sullivan Coyne, James H. Doroshow

Publikováno v: Journal of Clinical Oncology. 36:2587-2587

2587Background: Wee1 tyrosine kinase promotes G2 cell cycle arrest following DNA damage via inactivating phosphorylation of cyclin-dependent kinase 1. We are conducting a phase I study of the oral ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::211eba5f9d51391bc31cb17455f0dc4f
https://doi.org/10.1200/jco.2018.36.15_suppl.2587